NDA 219847 · Azurity
Arynta
Lisdexamfetamine Dimesylate · Oral
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
117
33 Phase 3, 5 recruiting
FAERS reports
3
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION ARYNTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ARYNTA, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ARYNTA, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ARYNTA treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 )]. WARNING: ABUSE, MISUSE, AND ADDICTION See...
What it is approved for
From the label in effect Jul 30, 2025.
ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies ( 14.1 )] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies ( 14.2 )] . Limitations of Use: The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.4 )] . ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established [see Warnings and Precautions ( 5.2 )] . ARYNTA is a central nervous system (CNS) stimulant indicated for the treatment of ( 1 ): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Moderate to severe binge eating disorder (BED) in adults Limitations of Use : The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ) ARYNTA is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established ( 5.2 )
Mechanism: Lisdexamfetamine is a prodrug of dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 2025 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- ARYNTA · LISDEXAMFETAMINE DIMESYLATE 10MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lisdexamfetamine Dimesylate" as an intervention, any sponsor and status, largest first.
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
- Open Label Extension in Adults With Binge Eating Disorder (BED)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01657019 · 604 participants · Start Aug 21, 2012 · Primary completion Oct 21, 2014
Drug: Lisdexamfetamine dimesylate · For: Binge Eating Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 89 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552902 · 549 participants · Start Apr 3, 2012 · Primary completion May 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Tucson, Arizona; Little Rock, Arkansas · 95 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552915 · 464 participants · Start Apr 17, 2012 · Primary completion Jan 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; National City, California · 79 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial flutter1
- cardiac failure congestive1
- insurance issue1
- middle insomnia1
- product use issue1
- pulmonary oedema1
- rash1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of the safety of lisdexamfetamine dimesylate.
Coghill DR, Caballero B, Sorooshian S, et al. · CNS Drugs 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD.
Madaan V, Bhaskar S, Donnelly GAE, et al. · J Atten Disord 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
Schein J, Cloutier M, Gauthier-Loiselle M, et al. · J Comp Eff Res 2024 · Comparative Study, Randomized Controlled Trial
- Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
Ichikawa H, Miyajima T, Yamashita Y, et al. · J Child Adolesc Psychopharmacol 2020 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.
Faraone SV · J Atten Disord 2012 · Meta-Analysis, Research Support, N.I.H., Extramural
- Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.
Schneider E, Higgs S, Dourish CT · Eur Neuropsychopharmacol 2021 · Meta-Analysis, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.